Quotient Sciences and Acesion Pharma Announce Collaboration on AI-Enhanced Formulation Development to Advance Atrial Fibrillation Pipeline

New AI-enhanced solution helps identify promising drug formulations, compressing early clinical decision-making for new treatments

NOTTINGHAM, England, Oct. 2, 2026 /PRNewswire/ -- Quotient Sciences, a global integrated CRDMO (contract research, development and manufacturing organization), and Acesion Pharma, a Copenhagen-based biotech company developing treatments for cardiac arrhythmia, today announced a new collaboration applying Quotient Sciences' AI-enhanced formulation development solution within its Translational Pharmaceutics® platform.

The collaboration supports Acesion's early-stage pipeline of small molecules targeted towards atrial fibrillation, the world's most common sustained cardiac arrhythmia.

The collaboration reflects both companies' shared commitment to advancing innovation in early drug development. Quotient Sciences' AI-enhanced formulation development solution applies active machine learning (ML) with Bayesian optimization to help identify and prioritize the drug products most likely to succeed in the clinic, enabling partners such as Acesion to make faster, better-informed decisions earlier in development.

Atrial fibrillation: a growing global health challenge

The lifetime risk of developing atrial fibrillation is approximately one in three adults over age 55, making it one of the most common cardiovascular disorders associated with age.

Patients with atrial fibrillation face an approximately five-fold increased risk of stroke, making effective management critical for reducing serious complications. Atrial fibrillation impacts an estimated 50-60 million people globally.

AI-enhanced formulation development within Translational Pharmaceutics®

Quotient Sciences' Translational Pharmaceutics® platform optimizes drug development by integrating a range of drug product formulation and clinical activities. It has been used by biotech and pharmaceutical companies globally as a proven method for advancing candidates through early development for more than 20 years.

Now enhanced with Quotient Sciences' new AI-enhanced formulation development solution, Translational Pharmaceutics® allows development teams to analyze data and predict formulation performance earlier and more precisely, shortening development timelines further while supporting better-informed decisions. Early development activities can be focused on the drug product candidates with the highest chances of clinical success.

A collaboration built on innovation

Dr. Andrew Lewis, Chief Scientific Officer at Quotient Sciences, said: "This collaboration with Acesion Pharma reflects exactly what our AI-enhanced formulation development solution, combined with Translational Pharmaceutics®, is designed to deliver: helping our partners make better-informed, faster decisions about their drug product formulations. We're proud to be working with Acesion on a shared commitment to innovation, and to support their pipeline in the field of atrial fibrillation."

Dr. Elisabeth V. Carstensen, Vice President CMC, at Acesion Pharma said: "We are excited to, together with Quotient Sciences, explore how their AI-enhanced algorithms can help guide and accelerate oral formulation development for our small-molecule compounds. By helping to guide and accelerate development decisions, this approach has the potential to shorten timelines for clinical testing and increase the likelihood of achieving the desired product profile."

About Acesion Pharma

Acesion Pharma is a privately held Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia. Acesion aims to develop first-in-class SK channel inhibitors as a more efficacious, safe and tolerable treatment of AF. Existing drugs generally have a limited effect and are associated with risk of serious adverse events, and there is a considerable patient need for developing better and safer drugs. Acesion is the only company successfully progressing SK ion channel inhibitors into clinical trials and has demonstrated human proof-of-concept with its first-generation SK ion channel inhibitor AP30663 in pharmacological AF cardioversion (https://www.nature.com/articles/s41591-023-02679-9).

About Quotient Sciences

Quotient Sciences is an integrated CRDMO (contract research, development and manufacturing organization) providing services across the entire drug development and clinical pathway. Our flagship platform for drug development, Translational Pharmaceutics®, has been trusted by companies ranging from emerging biotechs to Fortune 50 pharmaceutical organizations for integrated drug product formulation, manufacturing and clinical testing. Enhanced with our new AI-driven formulation insights and backed by more than 20 years of experience, Translational Pharmaceutics® helps sponsors make better decisions earlier and advance towards proof-of-concept studies while reducing early development time, cost and risk. To learn more, visit quotientsciences.com.

Source: Quotient Sciences Global News